StocksMedium•6 October 2026•
1 min read
Aardvark Therapeutics Faces Class Action Lawsuit After FDA Clinical Hold
Key Facts
1Aardvark Therapeutics faces a securities class action lawsuit alleging it misled investors regarding the safety of its experimental drug.
2The FDA imposed a full clinical hold on the HERO trial following cardiac observations that paused the study.
Aardvark Therapeutics faces a securities class action lawsuit alleging it misled investors regarding the safety of its experimental drug, ARD-101. GlobeNewswire reported that the FDA imposed a full clinical hold on the HERO trial following cardiac observations that paused the study, contradicting previous company claims regarding the treatment's safety profile.
The lawsuit alleges the company falsely represented that the drug was 99% gut-restricted with no serious adverse events. Shares of AARD closed at $5.22 on October 5, 2026, as the firm navigates legal and regulatory challenges following its earlier announcement of a voluntary trial pause that preceded the formal FDA intervention.